
Amy E. Juedes
Examiner (ID: 10106, Phone: (571)272-4471 , Office: P/1644 )
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644 |
| Total Applications | 1257 |
| Issued Applications | 438 |
| Pending Applications | 162 |
| Abandoned Applications | 699 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19955349
[patent_doc_number] => 12325756
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-10
[patent_title] => Use of trans-signaling approach in chimeric antigen receptors
[patent_app_type] => utility
[patent_app_number] => 18/048233
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 17
[patent_no_of_words] => 24010
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048233
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048233 | Use of trans-signaling approach in chimeric antigen receptors | Oct 19, 2022 | Issued |
Array
(
[id] => 18726157
[patent_doc_number] => 20230340413
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/968410
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10688
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17968410
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/968410 | OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF | Oct 17, 2022 | Abandoned |
Array
(
[id] => 18309478
[patent_doc_number] => 20230113378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => Methods Of Treating Multiple Sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/962641
[patent_app_country] => US
[patent_app_date] => 2022-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10761
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17962641
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/962641 | Methods Of Treating Multiple Sclerosis | Oct 9, 2022 | Pending |
Array
(
[id] => 18451520
[patent_doc_number] => 20230192798
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS
[patent_app_type] => utility
[patent_app_number] => 17/938536
[patent_app_country] => US
[patent_app_date] => 2022-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938536
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/938536 | ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS | Oct 5, 2022 | Abandoned |
Array
(
[id] => 18523013
[patent_doc_number] => 20230233667
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => CORONAVIRUS VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/940967
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17940967
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/940967 | CORONAVIRUS VACCINE | Sep 7, 2022 | Abandoned |
Array
(
[id] => 18184958
[patent_doc_number] => 20230045688
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => CUSTOMMUNE: A WEB TOOL FOR DESIGNING PERSONALIZED AND POPULATION-TARGETED PEPTIDE VACCINES
[patent_app_type] => utility
[patent_app_number] => 17/901094
[patent_app_country] => US
[patent_app_date] => 2022-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6804
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17901094
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/901094 | CUSTOMMUNE: A WEB TOOL FOR DESIGNING PERSONALIZED AND POPULATION-TARGETED PEPTIDE VACCINES | Aug 31, 2022 | Pending |
Array
(
[id] => 18485185
[patent_doc_number] => 20230212512
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => REGULATORY T CELL EPITOPES
[patent_app_type] => utility
[patent_app_number] => 17/893579
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17893579
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/893579 | Regulatory T cell epitopes | Aug 22, 2022 | Issued |
Array
(
[id] => 18816073
[patent_doc_number] => 20230390412
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => COMPOSITIONS AND METHODS FOR ALLOGENEIC TRANSPLANTATION
[patent_app_type] => utility
[patent_app_number] => 17/820540
[patent_app_country] => US
[patent_app_date] => 2022-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59721
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820540
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820540 | COMPOSITIONS AND METHODS FOR ALLOGENEIC TRANSPLANTATION | Aug 16, 2022 | Pending |
Array
(
[id] => 19594417
[patent_doc_number] => 12152247
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-26
[patent_title] => NF-
[patent_app_type] => utility
[patent_app_number] => 17/871680
[patent_app_country] => US
[patent_app_date] => 2022-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 19
[patent_no_of_words] => 9522
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17871680
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/871680 | NF- | Jul 21, 2022 | Issued |
Array
(
[id] => 18530016
[patent_doc_number] => 20230235084
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES
[patent_app_type] => utility
[patent_app_number] => 17/864389
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864389
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/864389 | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES | Jul 12, 2022 | Pending |
Array
(
[id] => 17982834
[patent_doc_number] => 20220348870
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => MATERIALS AND METHODS FOR MODIFYING THE ACTIVITY OF T CELLS
[patent_app_type] => utility
[patent_app_number] => 17/863558
[patent_app_country] => US
[patent_app_date] => 2022-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10670
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863558
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/863558 | MATERIALS AND METHODS FOR MODIFYING THE ACTIVITY OF T CELLS | Jul 12, 2022 | Abandoned |
Array
(
[id] => 18212510
[patent_doc_number] => 20230058774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => NOVEL DOMINANT NEGATIVE FAS POLYPEPTIDES, CELLS COMPRISING THEREOF AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/858320
[patent_app_country] => US
[patent_app_date] => 2022-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31421
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858320
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/858320 | NOVEL DOMINANT NEGATIVE FAS POLYPEPTIDES, CELLS COMPRISING THEREOF AND USES THEREOF | Jul 5, 2022 | Pending |
Array
(
[id] => 20316037
[patent_doc_number] => 12454579
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-28
[patent_title] => Compositions and methods for inhibiting T cell exhaustion
[patent_app_type] => utility
[patent_app_number] => 17/850825
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 62
[patent_figures_cnt] => 154
[patent_no_of_words] => 27946
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850825
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850825 | Compositions and methods for inhibiting T cell exhaustion | Jun 26, 2022 | Issued |
Array
(
[id] => 19379301
[patent_doc_number] => 20240269171
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => EPSTEIN-BARR VIRUS (EBV) ANTIGEN COMPOSITES AND DENDRITIC CELL (DC)-BASED VACCINE, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/574764
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18574764
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/574764 | Epstein-Barr virus (EBV) antigen composites and dendritic cell (DC)-based vaccine, and use thereof | Jun 16, 2022 | Issued |
Array
(
[id] => 18283049
[patent_doc_number] => 20230098521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/841447
[patent_app_country] => US
[patent_app_date] => 2022-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51243
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841447
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/841447 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | Jun 14, 2022 | Abandoned |
Array
(
[id] => 18349220
[patent_doc_number] => 20230137331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => Activation and Expansion of T Cell Subsets Using Biocompatible Solid Substrates with Tunable Rigidity
[patent_app_type] => utility
[patent_app_number] => 17/839397
[patent_app_country] => US
[patent_app_date] => 2022-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17839397
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/839397 | Activation and Expansion of T Cell Subsets Using Biocompatible Solid Substrates with Tunable Rigidity | Jun 12, 2022 | Abandoned |
Array
(
[id] => 18036513
[patent_doc_number] => 20220380728
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => COMPOSITIONS AND METHODS FOR IN VITRO CULTIVATION AND/OR EXPANSION OF REGULATORY T CELLS
[patent_app_type] => utility
[patent_app_number] => 17/836176
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18870
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836176
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836176 | COMPOSITIONS AND METHODS FOR IN VITRO CULTIVATION AND/OR EXPANSION OF REGULATORY T CELLS | Jun 8, 2022 | Abandoned |
Array
(
[id] => 18351626
[patent_doc_number] => 20230139737
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => BINDING PROTEINS SPECIFIC FOR RAS NEOANTIGENS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/832214
[patent_app_country] => US
[patent_app_date] => 2022-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33172
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17832214
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/832214 | BINDING PROTEINS SPECIFIC FOR RAS NEOANTIGENS AND USES THEREOF | Jun 2, 2022 | Abandoned |
Array
(
[id] => 18056483
[patent_doc_number] => 20220387569
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => INDUCED PLURIPOTENT STEM CELL-BASED CANCER VACCINES
[patent_app_type] => utility
[patent_app_number] => 17/827957
[patent_app_country] => US
[patent_app_date] => 2022-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17827957
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/827957 | INDUCED PLURIPOTENT STEM CELL-BASED CANCER VACCINES | May 29, 2022 | Abandoned |
Array
(
[id] => 18093412
[patent_doc_number] => 20220411753
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => TRANSGENIC T CELL AND CHIMERIC ANTIGEN RECEPTOR T CELL COMPOSITIONS AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 17/824650
[patent_app_country] => US
[patent_app_date] => 2022-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17824650
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/824650 | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods | May 24, 2022 | Issued |